Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
With the introduction of long-term subcutaneous administration of deferoxamine (DFO), there has been a decline in the morbidity and mortality of transfusion-dependent beta-thalassemia patients. However, since the use of subcutaneous DFO is hindered by poor compliance, long-term i.v. DFO therapy has been attempted in order to improve compliance, prevent excessive iron accumulation and extend survival. Thirteen patients (aged 5.4-18.4 years) were started on i.v. home administration of DFO (100 mg/kg per day) via an exteriorized, tunneled right atrial catheter (Hickman type). After a median follow-up of 36 months, the mean ferritin levels had dropped significantly (5,117 +/- 1,737 to 1,816 +/- 1,062 micrograms/l. P = 0.0001). None of the patients developed new endocrine or cardiac diseases due to iron overload. Patients beginning therapy at an early age (< or = 11 years) showed a tendency for improved growth parameters at the end of the treatment period. Two patients developed moderately high frequency sensorineural hearing loss. One patient developed a right atrial thrombus. The line infection rate was low (1.7 episodes per 1,000 patients days). In view of the grave prognosis for iron overloaded patients and the fact that oral chelators are not yet readily available, we recommend this form of therapy for the young, noncompliant beta-thalassemia patient, despite the occasional complications observed.
Tamary
H
H
Sambur Center for Pediatric Hematology and Oncology, Children's Medical Center of Israel, Petah Tikva.
Goshen
J
J
Carmi
D
D
Yaniv
I
I
Kaplinsky
C
C
Cohen
I J
IJ
Zaizov
R
R
D000293:Adolescent; D001803:Blood Transfusion; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010349:Patient Compliance; D013997:Time Factors; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000628:therapy
D003676:Deferoxamine